Search Results
Your search for The ASCO ,The ASCO matches 20570 pages
Showing 3001 - 3050CAIRO5 Determines Optimal Approach to Colorectal Liver Metastases
In the phase III CAIRO5 study, conducted by the Dutch Colorectal Cancer Group, triplet vs doublet chemotherapy plus bevacizumab significantly increased progression-free survival, response rate, and the rate of R0/R1 resections, with and without ablation, in patients with initially unresectable...
Nicholas J. Short, MD, on ALL: Updated Phase II Study Results on Ponatinib and Blinatumomab
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses updated results from a phase II study that suggests the chemotherapy-free regimen of simultaneous ponatinib and blinatumomab is safe and effective in patients with Philadelphia chromosome–positive acute...
Study Sheds Light on Mechanisms Driving Cancer Induced by Organic Solvent Used in Printing Industry
1,2-Dichloropropane (1,2-DCP) is a synthetic organic solvent used in the printing industry. It was linked to cholangiocarcinoma in 2013, when printing company employees in Osaka, Japan, exposed to 1,2-DCP were diagnosed with the cancer. Thereafter, the International Agency for Research on Cancer...
Study Examines Role of Per- and Polyfluoroalkyl Substances in Development of Cancer, Health-Care Costs
Daily exposure to a class of chemicals used in the production of many household items may lead to cancer, thyroid disease, and childhood obesity, a new study published by Obsekov et al in the journal Exposure and Health showed. The resulting economic burden is estimated to cost Americans a minimum...
Investigational Blood Test May Help Improve Diagnosis and Monitoring of Glioma
Researchers at Massachusetts General Hospital (MGH) who previously developed a blood test for mutations in a gene linked to gliomas have now applied their technology to detect additional mutations—in this case, in the gene that codes for the epidermal growth factor receptor (EGFR). The advance,...
Rami Manochakian, MD, on NSCLC: Clinical Implications of Findings on Nivolumab Plus Chemotherapy
Rami Manochakian, MD, of Mayo Clinic Florida, discusses the phase II findings of the NADIM II trial, which confirmed that, in terms of pathologic complete response as well as the feasibility of surgery, combining nivolumab and chemotherapy was superior to chemotherapy alone as a neoadjuvant...
ECHELON-1 Trial: Brentuximab Vedotin With Chemotherapy Offers Survival Benefit in Stage III or IV Hodgkin Lymphoma
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (a regimen known as A+AVD) significantly reduced the risk of mortality vs standard treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with previously untreated stage III or IV classical Hodgkin...
Expert Point of View: Claudine Isaacs, MD
The invited discussant of PALOMA-2 was Claudine Isaacs, MD, Professor of Medicine and Oncology at Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC. Dr. Isaacs examined the findings in context of the MONALEESA trials, which showed an overall survival benefit with...
PALOMA-2: No Overall Survival Benefit Reported With Palbociclib/Letrozole in Advanced Breast Cancer
The final overall survival analysis of the phase III PALOMA-2 trial has shown no significant benefit for palbociclib given with letrozole, vs letrozole and placebo, as a first-line treatment in hormone receptor–positive, HER2-negative metastatic breast cancer.1 The results were reported at the 2022 ...
Downstaging Hepatocellular Carcinoma Prior to Liver Transplant: 10-Year Outcomes
In some patients with hepatocellular carcinoma, downstaging of disease to within criteria that qualify the patient for a liver transplant leads to excellent 10-year posttransplant outcomes, according to new research published by Tabrizian et al in JAMA Surgery. The results validate current national ...
New Poster Track at JADPRO Live Announced: APSHO Patient/Advocacy Perspective
Abstract submission is now open for JADPRO Live 2022, taking place October 20 to 23 in Aurora, Colorado, and includes a new poster track: APSHO Patient/Advocacy Perspective Posters. This track provides patients and patient advocates a platform to share perspectives on their care with over 1,500...
AMA House of Delegates Approves ASCO-Backed Resolutions on Ancillary Clinical Trial Costs and ARPA-H Funding
From June 10 to 15, delegates from the Association for Clinical Oncology (ASCO) participated in the 2022 Annual Meeting of the American Medical Association’s (AMA) House of Delegates (HOD). The AMA HOD is the principal policy-making body of AMA and meets twice a year to discuss pressing issues and...
ASCO Guideline Update Supports New Second- and Third-Line Treatments for HER2-Positive Breast Cancer
ASCO has issued a new practice guideline update on the use of systemic therapy for HER2-positive breast cancer, just 4 years after the previous practice guideline update was released in 2018.1,2 This latest update reviews results from multiple clinical trials published between 2016 and 2021 that...
ASCO Statement on Supreme Court Decision in Dobbs v Jackson Women’s Health Organization
On June 27, 2022, ASCO released a statement on the recent ruling in Dobbs v Jackson Women’s Health Organization. “ASCO is committed to the delivery of medically appropriate, equitable, evidence-based cancer care. For patients of child-bearing age, a cancer diagnosis raises medical considerations...
CAR T-Cell Reimbursement, Measuring Health Disparities, Digital Quality in Focus in Comments on 2023 Hospital Inpatient Payment Proposal
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to the fiscal year (FY) 2023 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. ASCO’s comments address...
Study Finds Radiation Therapy May Be Safely Omitted for Some Older Patients With Luminal A Breast Cancer
For some patients aged 55 or older with early-stage, low-risk breast cancer, endocrine therapy following breast-conserving surgery may be sufficient without the need for postoperative radiation therapy, according to the results of the prospective LUMINA trial, reported at the 2022 ASCO Annual...
Medical Costs and Clinical Value: Playing the Long Game
Even as soaring medical costs strain public and private budgets around the world, patients yearn for therapeutic breakthroughs. Game-changing cancer treatments, emerging antiviral agents, and mRNA vaccines are powerful reminders of medical technology’s potential. But insurance premiums and...
Changing the Natural History of ER-Positive, HER2-Negative Breast Cancer With the Introduction of CDK4/6 Inhibition
It has been 14 years since a collaboration between the University of California, Los Angeles (UCLA) and Pfizer identified a unique role for cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in estrogen receptor (ER)-positive human cell line models and demonstrated that these agents act...
Hematology Highlights From ASCO 2022
A multitude of presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage in The ASCO Post of the major news stories at the meeting, here we offer summaries of additional studies of special interest...
ASCO 2022: Conversations in Gynecologic Oncology
In this episode, we’re featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube ...
Study Reports Time-Limited Venetoclax-Based Regimens of Benefit in Front-Line Treatment of CLL
Time-limited venetoclax-based regimens provide deeper and more durable remissions than chemoimmunotherapy combinations in patients with previously untreated chronic lymphocytic leukemia (CLL), regardless of patients’ fitness, according to late-breaking data presented during the European Hematology...
Adherence to VTE Prophylaxis Guidelines After Pancreatic Cancer Surgery
In a U.S. retrospective cohort study reported in JAMA Surgery, Perry et al found that a very small percentage of patients filled prescriptions for guideline-recommended venous thromboembolism (VTE) prophylaxis after undergoing surgery for pancreatic cancer. As stated by the investigators, “VTE is...
Researchers Discover Protein That May Be Associated With Better Prognosis for Patients With Ovarian Cancer
Researchers have discovered that a protein associated with metabolism—and formerly recognized as a potential therapeutic target for ovarian cancer—may instead be associated with a better prognosis for patients with the malignancy. In a report published by Clemente et al in Cancer Research...
Survey Finds More Than 80% of Patients With Cancer and Survivors Say Copay Assistance Programs Help Them Afford Their Prescription Drugs
A new Survivor Views survey from the American Cancer Society Cancer Action Network (ACS CAN) showed that a majority of respondents (83%) who had applied to a copay assistance program and were accepted said the assistance enables them to get the medication they otherwise couldn’t afford. However,...
ASCO Endorses President Biden’s Pick of ASCO Past President Monica M. Bertagnolli, MD, FACS, FASCO, as Incoming Head of National Cancer Institute
Clifford A. Hudis, MD, FACP, FASCO, Chief Executive Officer of ASCO, issued the following statement on July 21: ASCO applauds President Biden for his reported decision to appoint ASCO Past President Monica M. Bertagnolli, MD, FACS, FASCO, as the new Director of the National Cancer Institute...
Adjuvant Everolimus Narrowly Misses Statistical Significance in RCC, Except for Very High–Risk Patients
In the phase III EVEREST trial, adjuvant everolimus improved median recurrence-free survival in patients with resected renal cell carcinoma (RCC), but this finding failed to be statistically significant in the total study population of 1,499 patients, according to a prespecified boundary. However,...
Does Disclosing Maternal Status Affect Children’s Health Behaviors?
Telling children about their mother’s risk of hereditary breast and/or ovarian cancer does not adversely influence the offspring’s lifestyle or quality of life in the long term, according to a new study published by McDonnell et al in the journal Pediatrics. The study looked at the mutation status...
Judging Melanoma Thickness: Comparison of Dermatologists and Machine-Learning Algorithm
Assessing the thickness of melanoma is difficult—whether done by an experienced dermatologist or a well-trained machine-learning algorithm. A study published by Polesie et al in the Journal of the European Academy of Dermatology and Venereology showed that an algorithm and a group of approximately...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Two Early-Career Cancer Researchers From Africa Aim to Make a Difference and Never Give Up
In countries with a high income, research in oncology is sponsored by funding agencies and industry, which has meaningfully improved survival outcomes of patients with cancer. In contrast, the African continent is disadvantaged in all aspects of human development, particularly in the fields of...
CancerCare’s Caregiver Decision-Making Survey Results Reveal Gaps in Support for Caregivers, Give Rise to Recommendations for Improving Caregiver Support
CancerCare has released a report entitled “Cancer Caregivers: National Research Report on Shared Treatment Decision-Making.” It details the findings of its caregiver decision-making survey, which polled a nationally representative sample of 2,703 cancer caregivers between February and July 2021....
Caregivers for Patients With Multiple Myeloma Face Mental Health Challenges
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published by O’Donnell in Blood Advances. Although medical professionals have long acknowledged the toll a serious or terminal diagnosis can have...
Affirming Health Equity: A Model for Integrative Health Care
Guest Editor’s Note: Despite the increasing use of complementary modalities that include mind-body therapies and natural products, significant disparities exist in integrative health care. Contributing factors include access to care and affordability. In this installment of The ASCO Post’s...
For Medicaid-Insured Patients With Cancer, Health Insurance Does Not Always Mean Health-Care Access
Although there has been a significant increase in the number of U.S. residents insured through Medicaid since the Patient Protection and Affordable Care Act was signed into law in March 2010, the ability of Medicaid-insured patients to access cancer care services has not been well understood. In a...
Study Examines Quality-of-Life Outcomes Among Patients Participating in Phase III Randomized Trials of Cancer Drugs
In an analysis that evaluated the outcomes of anticancer drug studies in the advanced disease setting with regard to patient quality of life (QOL), improved QOL outcomes were associated with improved overall survival but not with improved progression-free survival. Almost half of the studies that...
Research Examines Which Demographic Is Most Likely to Use Medical Aid in Dying
Researchers analyzed data from each of the 5,329 patients across the United States who used medical aid in dying in the 23 years after Oregon became the first state to legalize the practice (in 1997) and found one demographic dominates the group: well-educated, White patients with cancer. These...
Deciphering the Elusive Origin and Pathways of Brain Metastases
The effective treatment of patients with brain metastases is an unmet need because, until fairly recently, patients with brain metastases were excluded from clinical trials of systemic therapies. However, the emergence of molecular targeted therapies has allowed a new treatment approach in patients ...
ASCO 2022: Conversations in Genitourinary Oncology
In this episode, we’re featuring two conversations from leaders in the field of genitourinary oncology. These discussions go over long-term findings in prostate cancer and urothelial carcinoma and were both presented at the 2022 ASCO Annual Meeting.
New Antibody Therapy Shows Activity in Patients With Medulloblastoma
Effective and safe treatments are needed for medulloblastoma—the most common type of cancerous brain tumor in children—especially for patients whose cancer has spread to the spinal cord. A recent phase I clinical trial has generated promising results for a new blocking antibody therapy that targets ...
New Report Underscores Importance of Health Insurance Status and Cancer Stage at Diagnosis in Relation to Patient Survival
A new report published by Jingxuan Zhao, MPH, and colleagues in CA: A Cancer Journal for Clinicians showed that individuals without health insurance coverage were significantly more likely to be diagnosed with late-stage cancer and have worse survival rates after cancer diagnosis compared to...
FDA Approves Crizotinib for ALK-Positive Inflammatory Myofibroblastic Tumors
On July 14, 2022, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori) for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors. Two Trials The safety and...
Expert Point of View: Susan Slovin, MD, PhD
Invited discussant Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, pointed out there are no relevant serum biomarkers for disease progression and the challenges of interpreting response in metastatic castration-resistant prostate cancer. “We should have more definitive...
LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted
On July 13, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, adjuvanted, for the prevention of COVID-19 caused by SARS–CoV-2 in individuals aged 18 years and older. “Authorizing an additional COVID-19 vaccine expands the...
Study Reveals Cancer Screening Decreased Worldwide During Height of COVID-19 Pandemic
A study that surveyed cancer screening data included in medical journals worldwide from January 2020 into December 2021 showed significant decreases in the number of screenings for breast, colorectal, and cervical cancers during the early phase of the COVID-19 pandemic. The findings of the study,...
President Biden Appoints Cancer Panel Members, and Cancer Cabinet Unveils Priority Actions
On July 13, President Joe Biden announced his intent to appoint Mitchel Berger, MD; Carol Brown, MD; and Elizabeth M. Jaffee, MD, to the President’s Cancer Panel. The three are distinguished members of the scientific, research, and public health communities appointed by the President to advise him...
Expert Point of View: Madhav V. Dhodapkar, MBBS
“BCMA-targeting bispecific antibodies work, showing impressive single-agent activity in heavily pretreated multiple myeloma. This class of agents is likely to become an important component of future antimyeloma therapies, but we must learn how to optimally use them,” said Madhav V. Dhodapkar,...
Responses to Teclistamab Reported in Early-Phase Trial of Highly Refractory Multiple Myeloma
In patients with multiple myeloma exposed or refractory to three standard therapies, treatment with the bispecific antibody teclistamab produced strong and durable responses in the phase I/II MajesTEC-1 study.1 The results of weekly subcutaneous dosing of teclistamab in 165 patients were presented...
Bradley J. Monk, MD, on Ovarian Cancer: New Data on Rucaparib Monotherapy vs Placebo as Maintenance Treatment
Bradley J. Monk, MD, of the University of Arizona College of Medicine and Creighton University School of Medicine, discusses phase III findings from the ATHENA–MONO (GOG-3020/ENGOT-ov45) trial. It showed that rucaparib as first-line maintenance treatment, following first-line platinum-based...
Michael Dickinson, MBBS, on DLBCL: Phase II Expansion Results on Glofitamab
Michael Dickinson, MBBS, of the Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and The University of Melbourne, discusses new data, which showed that fixed-duration glofitamab induces durable complete remissions with a favorable safety profile in patients with or refractory diffuse...
